ReviewBrain sciences2022
Relapsing High-Grade Glioma from Peritumoral Zone: Critical Review of Radiotherapy Treatment Options.
Review in Brain sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 17 citations in OpenAlex.
- Single Institution Retrospective Study to Determine Time to First True Progression in MGMT-Methylated Glioblastoma Patients Who Received Standard of Care.Journal of clinical medicine · 2026Article
- Article
- MRI and PET Alterations in Adult Skull Base Tumors: A Narrative Review of Proton Versus Photon Radiotherapy.Diagnostics (Basel, Switzerland) · 2026Review
- Beyond morphology: imaging the glioblastoma microenvironment in the era of quantitative neuro-oncology.Frontiers in medicine · 2026Review
- Metabolic Heterogeneity in High-Grade Glioma Assessed by Multi-Tracer PET and Ex Vivo Metabolomics: A Systematic Review and Meta-Analysis.Metabolites · 2025Review
- Precision Oncology for High-Grade Gliomas: A Tumor Organoid Model for Adjuvant Treatment Selection.Bioengineering (Basel, Switzerland) · 2025Article
- Brainstem Glioma Prognostication: Static FET PET/CT.Cancers · 2025Article
- Radiotherapy in Glioblastoma Multiforme: Evolution, Limitations, and Molecularly Guided Future.Biomedicines · 2025Review
- Multimodal radiomics in glioma: predicting recurrence in the peritumoural brain zone using integrated MRI.BMC medical imaging · 2025Article
- Optimizing Stereotactic Intracranial Neoplasm Treatment: A Systematic Review of PET Integration with Gamma Knife Radiosurgery.Diseases (Basel, Switzerland) · 2025Review
- Article
- Latest Advancements in the Management of H3K27M-Mutant Diffuse Intrinsic Pontine Glioma: A Narrative Review.Cancers · 2025Review
- Daily iron supplementation for prevention or treatment of moderate iron deficiency anemia in patients with solid neoplasm, undergoing concurrent radiochemotherapy treatment.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025Review
- Optic Nerve Glioblastoma with Optic Chiasm Involvement: A Case Report and a Brief Literature Review.Medicina (Kaunas, Lithuania) · 2024Review
- Multiparametric simultaneous hybridQuantitative imaging in medicine and surgery · 2024Article
- Preferred Imaging for Target Volume Delineation for Radiotherapy of Recurrent Glioblastoma: A Literature Review of the Available Evidence.Journal of personalized medicine · 2024Review
- The Role of Reirradiation in Childhood Progressive Diffuse Intrinsic Pontine Glioma (DIPG): An Ongoing Challenge beyond Radiobiology.Brain sciences · 2023Article
- Proton pump inhibitors display anti-tumour potential in glioma.Cell proliferation · 2023Review
- Editorial: Frontiers in Neuro Oncology and Neurosurgery.Brain sciences · 2023Article
- The peritumoral brain zone in glioblastoma: where we are and where we are going.Journal of neuroscience research · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most common and aggressive brain tumor in adults, with a median survival of about 15 months. After the prior treatment, GBM tends to relapse within the high dose radiation field, defined as the peritumoral brain zone (PTZ), needing a second treatment. In the present review, the primary role of ionizing radiation in recurrent GBM is discussed, and the current literature knowledge about the different radiation modalities, doses and fractionation options at our disposal is summarized. Therefore, the focus is on the necessity of tailoring the treatment approach to every single patient and using radiomics and PET/MRI imaging to have a relatively good outcome and avoid severe toxicity. The use of charged particle therapy and radiosensitizers to overcome GBM radioresistance is considered, even if further studies are necessary to evaluate the effectiveness in the setting of reirradiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.